Total Payments
$62,756
2024 Payments
$46,140
Companies
6
Transactions
35
Medicare Patients
12,923
Medicare Billing
$749,070
Payment Breakdown by Category
Research$62,435 (99.5%)
Food & Beverage$321.06 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $62,435 | 25 | 99.5% |
| Food and Beverage | $321.06 | 10 | 0.5% |
Payments by Type
Research
$62,435
25 transactions
General
$321.06
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $62,435 | 25 | $0 (2024) |
| Medtronic, Inc. | $164.28 | 1 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $72.69 | 5 | $0 (2019) |
| Biogen, Inc. | $32.63 | 2 | $0 (2018) |
| Siemens Medical Solutions USA, Inc. | $31.88 | 1 | $0 (2017) |
| Cardiovascular Systems Inc. | $19.58 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,140 | 12 | Regeneron Pharmaceuticals, Inc. ($46,140) |
| 2023 | $16,295 | 13 | Regeneron Pharmaceuticals, Inc. ($16,295) |
| 2021 | $183.86 | 2 | Medtronic, Inc. ($164.28) |
| 2019 | $19.92 | 1 | JAZZ PHARMACEUTICALS INC. ($19.92) |
| 2018 | $58.30 | 4 | Biogen, Inc. ($32.63) |
| 2017 | $58.98 | 3 | Siemens Medical Solutions USA, Inc. ($31.88) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $9,060.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 11/05/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,800.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,600.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 09/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,620.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 08/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,780.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $5,760.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $4,920.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $960.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 05/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $540.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 03/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $720.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 03/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 01/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $780.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 12/19/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $660.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 12/08/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $420.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 11/07/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $955.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/10/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $5,425.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 10/06/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 09/01/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $360.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 08/10/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $5,075.00 | Research |
| Study: AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | ||||||
| 08/10/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $340.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 08/01/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 07/11/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $180.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 07/11/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $60.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 07/04/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $420.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | Regeneron Pharmaceuticals, Inc. | $51,935 | 23 |
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $10,500 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 2,538 | 9,991 | $1.8M | $175,416 |
| 2022 | 58 | 3,475 | 13,889 | $2.3M | $223,511 |
| 2021 | 59 | 3,259 | 18,527 | $1.7M | $186,918 |
| 2020 | 62 | 3,651 | 19,471 | $1.5M | $163,225 |
Total Patients
12,923
Total Services
61,878
Medicare Billing
$749,070
Procedure Codes
302
All Medicare Procedures & Services
302 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74183 | Mri scan of abdomen before and after contrast | Office | 2023 | 100 | 104 | $295,174 | $27,883 | 9.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 22 | 22 | $58,773 | $25,689 | 43.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 139 | 140 | $187,180 | $9,322 | 5.0% |
| 72197 | Mri scan of pelvis before and after contrast | Office | 2023 | 33 | 33 | $91,485 | $7,957 | 8.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 110 | 111 | $141,858 | $6,988 | 4.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 28 | 28 | $8,418 | $6,596 | 78.4% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 23 | 23 | $26,725 | $5,947 | 22.3% |
| 74181 | Mri scan of abdomen without contrast | Office | 2023 | 40 | 40 | $77,513 | $5,178 | 6.7% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 66 | 66 | $86,856 | $4,426 | 5.1% |
| 77067 | Screening mammography | Office | 2023 | 36 | 36 | $14,466 | $4,425 | 30.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 20 | 20 | $18,388 | $4,336 | 23.6% |
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 131 | 133 | $67,032 | $3,968 | 5.9% |
| 77066 | Diagnostic mammography of both breasts | Office | 2023 | 32 | 32 | $13,792 | $3,767 | 27.3% |
| 74183 | Mri scan of abdomen before and after contrast | Facility | 2023 | 40 | 41 | $68,019 | $3,380 | 5.0% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 46 | 46 | $15,318 | $3,359 | 21.9% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2023 | 26 | 26 | $46,440 | $3,242 | 7.0% |
| 76642 | Limited ultrasound scan of 1 breast | Office | 2023 | 41 | 41 | $13,265 | $3,033 | 22.9% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 38 | 38 | $10,966 | $2,886 | 26.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 74 | 74 | $26,122 | $2,807 | 10.7% |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | Office | 2023 | 120 | 1,969 | $5,907 | $2,425 | 41.0% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 58 | 60 | $37,980 | $2,341 | 6.2% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 29 | 30 | $11,210 | $2,271 | 20.3% |
| 74181 | Mri scan of abdomen without contrast | Facility | 2023 | 41 | 41 | $33,743 | $2,199 | 6.5% |
| 77065 | Diagnostic mammography of 1 breast | Office | 2023 | 22 | 22 | $8,206 | $2,196 | 26.8% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 287 | 322 | $44,758 | $2,163 | 4.8% |
About Dr. Ashok Gupta, MD
Dr. Ashok Gupta, MD is a Diagnostic Radiology healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1447249495.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashok Gupta, MD has received a total of $62,756 in payments from pharmaceutical and medical device companies, with $46,140 received in 2024. These payments were reported across 35 transactions from 6 companies. The most common payment nature is "" ($62,435).
As a Medicare-enrolled provider, Gupta has provided services to 12,923 Medicare beneficiaries, totaling 61,878 services with total Medicare billing of $749,070. Data is available for 4 years (2020–2023), covering 302 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Other Specialties Diagnostic Radiology
- Location Greensboro, NC
- Active Since 10/20/2005
- Last Updated 10/14/2024
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1447249495
Products in Payments
- LIBTAYO (Biological) $51,935
- INTERSTIM (Device) $164.28
- Xyrem (Drug) $52.77
- SPINRAZA (Biological) $32.63
- Non-Product Specific (Device) $31.88
- XYREM (Drug) $19.92
- Diamondback Peripheral (Device) $19.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Greensboro
Dr. Donald Heck, Md, MD
Diagnostic Radiology — Payments: $102,318
Diagnostic Radiology $102,318
John Edmunds, Md, Phd, MD, PHD
Diagnostic Radiology — Payments: $34,833
Diagnostic Radiology $34,833
Heath Mccullough, Md, MD
Diagnostic Radiology — Payments: $17,232
Diagnostic Radiology $17,232
Dr. Sanjeev Deveshwar, Md, MD
Diagnostic Radiology — Payments: $9,342
Diagnostic Radiology $9,342
Dayne Hassell, Md, MD
Diagnostic Radiology — Payments: $4,168
Diagnostic Radiology $4,168
Adam Henn, Md, MD
Diagnostic Radiology — Payments: $2,564
Diagnostic Radiology $2,564